(Q51919331)

17 April 2018

title

Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. (English)

1 reference

17 April 2018

author

Peter Johannsen

1

1 reference

17 April 2018

Eric Salmon

2

1 reference

17 April 2018

Harald Hampel

3

1 reference

17 April 2018

author name string

Yikang Xu

4

1 reference

17 April 2018

Sharon Richardson

5

1 reference

17 April 2018

Suzanne Qvitzau

6

1 reference

17 April 2018

Rachel Schindler

7

1 reference

17 April 2018

AWARE Study Group

8

1 reference

17 April 2018

publication date

1 January 2006

1 reference

17 April 2018

published in

CNS Drugs

1 reference

17 April 2018

volume

20

1 reference

17 April 2018

issue

4

1 reference

17 April 2018

page(s)

311-325

1 reference

17 April 2018

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00005

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00005

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00005

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00005

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200620040-00005

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

12 December 2020

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1 reference

12 December 2020

Alzheimer Disease in the US Population

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Goal setting and attainment in Alzheimer's disease patients treated with donepezil

1 reference

12 December 2020

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

12 December 2020

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

12 December 2020

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

12 December 2020

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

12 December 2020

Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

1 reference

12 December 2020

Economic evaluation of donepezil in moderate to severe Alzheimer disease

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Galantamine for Alzheimer's disease.

1 reference

12 December 2020

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

1 reference

12 December 2020

Alzheimer's disease care: costs and potential savings.

1 reference

12 December 2020

Treatment of Alzheimer's disease

1 reference

12 December 2020

Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease.

1 reference

12 December 2020

1 reference

12 December 2020

Donepezil: tolerability and safety in Alzheimer's disease.

1 reference

12 December 2020

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

12 December 2020

Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil

1 reference

12 December 2020

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

12 December 2020

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

12 December 2020

Therapeutic continuity in Alzheimer's disease: switching patients to galantamine. Panel discussion: recommendations for prescribers

1 reference

12 December 2020

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

12 December 2020

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

12 December 2020

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

1 reference

12 December 2020

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

1 reference

12 December 2020

Current pharmacologic options for patients with Alzheimer's disease

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

Rivastigmine for Alzheimer's disease.

1 reference

12 December 2020

A new rating scale for Alzheimer's disease.

1 reference

12 December 2020

10.2165/00023210-200620040-00005

Identifiers

DOI

1 reference

17 April 2018

Dimensions Publication ID

1009267261

0 references

1 reference

17 April 2018